EP1786408A1 - Utilisation d'un modulateur selectif du recepteurs des oestrogenes dans la fabrication d'une preparation pharmaceutique utilisee dans une methode de traitement ou de prevention des insuffisances endrogeniques - Google Patents
Utilisation d'un modulateur selectif du recepteurs des oestrogenes dans la fabrication d'une preparation pharmaceutique utilisee dans une methode de traitement ou de prevention des insuffisances endrogeniquesInfo
- Publication number
- EP1786408A1 EP1786408A1 EP05771627A EP05771627A EP1786408A1 EP 1786408 A1 EP1786408 A1 EP 1786408A1 EP 05771627 A EP05771627 A EP 05771627A EP 05771627 A EP05771627 A EP 05771627A EP 1786408 A1 EP1786408 A1 EP 1786408A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- testosterone
- hypogonadism
- syndrome
- deficiency
- estrogen receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60690704P | 2004-09-03 | 2004-09-03 | |
FI20041216A FI20041216A0 (fi) | 2004-09-21 | 2004-09-21 | Menetelmä androgeenivajeen hoitoon tai estoon |
PCT/FI2005/000333 WO2006024689A1 (fr) | 2004-09-03 | 2005-07-20 | Utilisation d'un modulateur selectif du recepteurs des oestrogenes dans la fabrication d'une preparation pharmaceutique utilisee dans une methode de traitement ou de prevention des insuffisances endrogeniques |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1786408A1 true EP1786408A1 (fr) | 2007-05-23 |
EP1786408A4 EP1786408A4 (fr) | 2010-07-28 |
Family
ID=35999733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05771627A Withdrawn EP1786408A4 (fr) | 2004-09-03 | 2005-07-20 | Utilisation d'un modulateur selectif du recepteurs des oestrogenes dans la fabrication d'une preparation pharmaceutique utilisee dans une methode de traitement ou de prevention des insuffisances endrogeniques |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1786408A4 (fr) |
JP (1) | JP2008511615A (fr) |
KR (1) | KR20070059110A (fr) |
AU (1) | AU2005279178A1 (fr) |
BR (1) | BRPI0514701A (fr) |
CA (1) | CA2578852A1 (fr) |
MX (1) | MX2007002606A (fr) |
NO (1) | NO20071160L (fr) |
RU (1) | RU2007112114A (fr) |
WO (1) | WO2006024689A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101636372B (zh) | 2007-02-14 | 2013-03-27 | 霍尔莫斯医疗有限公司 | 有治疗价值的三苯基丁烯衍生物的制备方法 |
US20080312239A1 (en) * | 2007-06-13 | 2008-12-18 | Quatrx Pharmaceuticals Company | Methods for the treatment of erectile dysfunction using fispemifene |
CN102939287B (zh) | 2010-06-10 | 2016-01-27 | 塞拉根制药公司 | 雌激素受体调节剂及其用途 |
US9193714B2 (en) | 2011-12-14 | 2015-11-24 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
US9744177B2 (en) * | 2014-03-10 | 2017-08-29 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
EP3240771B1 (fr) | 2014-12-29 | 2019-02-20 | OLON S.p.A. | Procédé de préparation d'ospémifène et de fispémifène |
WO2023175010A1 (fr) * | 2022-03-15 | 2023-09-21 | Centre D'etude Des Cellules Souches (Cecs) | Utilisation du bazedoxifene pour augmenter la survie musculaire |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001036360A1 (fr) * | 1999-11-16 | 2001-05-25 | Hormos Medical Corporation | Derives de triphenylalcene et leur utilisation comme modulateurs selectifs des recepteurs aux oestrogenes |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL120262A (en) * | 1996-02-28 | 2001-01-28 | Pfizer | Droloxifene and derivatives thereof for use in increasing serum testosterone levels |
US6632447B1 (en) * | 1998-05-07 | 2003-10-14 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
CO5271697A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
JP2003534375A (ja) * | 2000-05-26 | 2003-11-18 | フィッチ,ハリー | 選択性抗エストロゲン薬を用いた男性におけるアンドロゲン欠乏症の治療法 |
US7067557B2 (en) * | 2000-05-26 | 2006-06-27 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
EP1666033B1 (fr) * | 2001-11-29 | 2008-12-31 | GTX, Inc. | Prevention et traitement de l'osteoporose induite par la privation d'androgene |
-
2005
- 2005-07-20 CA CA002578852A patent/CA2578852A1/fr not_active Abandoned
- 2005-07-20 EP EP05771627A patent/EP1786408A4/fr not_active Withdrawn
- 2005-07-20 AU AU2005279178A patent/AU2005279178A1/en not_active Abandoned
- 2005-07-20 KR KR1020077006922A patent/KR20070059110A/ko not_active Application Discontinuation
- 2005-07-20 JP JP2007529372A patent/JP2008511615A/ja not_active Abandoned
- 2005-07-20 WO PCT/FI2005/000333 patent/WO2006024689A1/fr active Application Filing
- 2005-07-20 BR BRPI0514701-8A patent/BRPI0514701A/pt not_active IP Right Cessation
- 2005-07-20 RU RU2007112114/15A patent/RU2007112114A/ru not_active Application Discontinuation
- 2005-07-20 MX MX2007002606A patent/MX2007002606A/es unknown
-
2007
- 2007-03-01 NO NO20071160A patent/NO20071160L/no not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001036360A1 (fr) * | 1999-11-16 | 2001-05-25 | Hormos Medical Corporation | Derives de triphenylalcene et leur utilisation comme modulateurs selectifs des recepteurs aux oestrogenes |
Non-Patent Citations (3)
Title |
---|
DUSCHEK ERIK J J ET AL: "Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men" EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 150, no. 4, April 2004 (2004-04), pages 539-546, XP002586475 ISSN: 0804-4643 * |
See also references of WO2006024689A1 * |
STEINER MITCHELL S ET AL: "Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia." CLINICAL PROSTATE CANCER JUN 2003 LNKD- PUBMED:15046680, vol. 2, no. 1, June 2003 (2003-06), pages 24-31, XP009134590 ISSN: 1540-0352 * |
Also Published As
Publication number | Publication date |
---|---|
MX2007002606A (es) | 2007-05-15 |
JP2008511615A (ja) | 2008-04-17 |
KR20070059110A (ko) | 2007-06-11 |
AU2005279178A1 (en) | 2006-03-09 |
BRPI0514701A (pt) | 2008-06-24 |
CA2578852A1 (fr) | 2006-03-09 |
EP1786408A4 (fr) | 2010-07-28 |
WO2006024689A1 (fr) | 2006-03-09 |
RU2007112114A (ru) | 2008-10-10 |
NO20071160L (no) | 2007-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Begam et al. | Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review | |
Komm et al. | An overview of current and emerging SERMs | |
EP1786408A1 (fr) | Utilisation d'un modulateur selectif du recepteurs des oestrogenes dans la fabrication d'une preparation pharmaceutique utilisee dans une methode de traitement ou de prevention des insuffisances endrogeniques | |
EP2106212B1 (fr) | Agents se liant aux récepteurs nucléaires | |
Suh et al. | Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer | |
Davis et al. | Clinical review 82: androgens and the postmenopausal woman | |
US9561238B2 (en) | Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy | |
FI118755B (fi) | Trifenyylietyleenejä käytettäväksi osteoporoosin ehkäisyyn ja hoitoon | |
KR101403893B1 (ko) | 4,17β-디히드록시안드로스트-4-엔-3-온에 대한 신규한 용도들 | |
US20060293294A1 (en) | Method for treatment or prevention of androgen deficiency | |
EP2819676B1 (fr) | Polythérapie pour le traitement d'une carence en androgène | |
CA2841572C (fr) | Metabolites du trans-clominophene et leurs utilisations | |
Bojkova et al. | Metformin in chemically-induced mammary carcinogenesis in rats | |
JP6025301B2 (ja) | 治療上の使用のためのc−19ステロイド | |
Clarke et al. | New selective estrogen and androgen receptor modulators | |
Wardley | FULVESTRANT: A REVIEW OF ITS DEVELOPMENT, PRE‐CLINICAL AND CLINICAL DATA | |
CN1168448C (zh) | 预防和/或治疗乳腺癌的含类固醇芳香酶抑制剂的药物 | |
CN1893955A (zh) | 用于预防和治疗激素依赖性疾病的包含孕酮受体拮抗剂和纯抗雌激素的组合物 | |
JP2001505574A (ja) | 17α−ジヒドロエキレニンを使用した神経退化および認識機能障害の予防方法 | |
Levin | Fulvestrant | |
Kumar et al. | Antiestrogen therapy for Breast Cancer: An overview. | |
US20230210870A1 (en) | Methods of treating female health conditions related to sex hormones | |
Sorbera et al. | Pipendoxifene | |
Laugier et al. | Dissociated effects of tamoxifen on growth and on progesterone receptor induction in quail oviduct | |
Buzdar | Hormonal therapy in early and advanced breast cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070306 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KOMI, JANNE Inventor name: BLOM, TARU Inventor name: LAMMINTAUSTA, RISTO |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/085 20060101AFI20100615BHEP Ipc: A61K 31/10 20060101ALI20100615BHEP Ipc: A61P 5/32 20060101ALI20100615BHEP Ipc: A61K 31/135 20060101ALI20100615BHEP Ipc: A61K 31/395 20060101ALI20100615BHEP Ipc: A61K 31/4164 20060101ALI20100615BHEP Ipc: A61P 5/26 20060101ALI20100615BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100628 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110126 |